Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00179699 · ClinicalTrials.gov registry record · Phase 1
Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Celgene Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00179699 is a Phase 1 study that was terminated before completion, run by Celgene Corporation. The registered enrollment target is 40 participants.
The verdict
NCT00179699, a Phase 1 study, was terminated before completion, sponsored by Celgene Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
Study will deteremine the MTD and evaluate the safety profile of oral lenalidomide on days 1-14 when combined with pemetrexed on day 1 of a 21 days cycle. Subjects will continue on study until documention of disease progression.
Interventions
- DRUG pemetrexed
- DRUG CC-5013
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-09 |
| Est. Completion | 2006-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00179699
The ClinicalTrials.gov registry entry for NCT00179699 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene Corporation, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pemetrexed is the first listed.
NCT00179699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00179699 about?
NCT00179699 is a clinical study titled "Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer". Study will deteremine the MTD and evaluate the safety profile of oral lenalidomide on days 1-14 when combined with pemetrexed on day 1 of a 21 days cycle. Subjects will continue on study until documention of disease progression.
What is the current status of trial NCT00179699?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2005-09. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00179699?
The interventions under investigation include: pemetrexed (DRUG), CC-5013 (DRUG).
Who is sponsoring clinical trial NCT00179699?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.